Drug Trial Radar · NCT07638553
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
172
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Jun 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. Psilocybin, a psychedelic, shows promising results in treating both depression and addiction. It may be particularly effective for preventing relapse in people with AUD who also have depressive symptoms after detoxification, offering quicker action than traditional antidepressants. The Psilocybin Alcohol Depression (PAD) pilot study, launched in February 2024, has provided critical insights for avoiding methodological flaws and demonstrated that psilocybin-assisted psychotherapy (PAP) is both feasible and acceptable. Preliminary efficacy analyses were conducted: at 12 weeks, the 25 mg group showed significantly greater reductions in drinking days (p = 0.038) and craving frequency (p = 0.045). Relapse rates were 35% in the 25 mg group and 50% in the control group (HR = 0.52 \[0.16-1.65\]). In the ERPPAD trial, the study authors will compare high-dose PAP with low-dose PAP in preventing relapse in individuals with AUD and depressive symptoms. The hypothesis is that high-dose PAP will be more effective than low-dose in preventing relapse over 6 months.
Conditions
- Alcohol Use Disorder
- Depressive Sympotoms
- Psilocybin
Interventions
Psilocybin (high dose)Drug
2 administrations of high-dose psilocybin (25 mg) 3 weeks apart
Psilocybin (low dose)Drug
2 administrations of low-dose psilocybin (3 mg) 3 weeks apart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of relapse between groupsTime frame: Month 6
- Time to relapse between groupsTime frame: Month 6
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier de la Côte Basque
Bayonne, France · Not yet recruiting
CHU Besançon
Besançon, France · Not yet recruiting
CHU de Bordeaux
Bordeaux, France · Not yet recruiting
CHU Brest
Brest, France · Not yet recruiting
CH Le Vinatier
Bron, France · Not yet recruiting
CHU de Nantes
Nantes, France · Not yet recruiting
CHU de Nîmes
Nîmes, France · Recruiting
CHU Saint-Etienne
Saint-Priest, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.